Can Prolia (denosumab) cause leg muscle weakness?

Prolia Does Not Directly Cause Leg Muscle Weakness

Prolia (denosumab) is not associated with causing leg muscle weakness as a direct adverse effect. The major adverse events documented in large clinical trials include infections, hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, and skin reactions—but not muscle weakness 1.

What the Evidence Shows

Documented Adverse Events from Clinical Trials

The FREEDOM trial and its 10-year extension, which followed thousands of patients on denosumab, systematically assessed adverse events and found no statistically significant increase in muscle-related complications 1. The documented adverse events include:

• Infections (slight increase in serious infections, RR 1.23,95% CI 1.00-1.52) 1
• Hypocalcemia (particularly in patients with chronic kidney disease) 1
• Osteonecrosis of the jaw (rare, approximately 5% in high-dose oncology settings, <1% in osteoporosis doses) 2
• Atypical femoral fractures (extremely rare) 3, 4
• Skin reactions (eczema, cellulitis, erysipelas) 1

Muscle Performance May Actually Improve

Interestingly, emerging research suggests denosumab may improve muscle strength rather than weaken it 5. A 2022 propensity score-matched study found that patients treated with denosumab showed:

• Significant increase in grip force (+5.1% vs -6.1% with vitamin D alone)
• Superior improvement in chair rising test force (+8.2% vs +0.9% with bisphosphonates)
• These effects appeared systemic rather than site-specific 5

This suggests denosumab might have beneficial effects on muscle performance in patients with low bone mineral density.

Important Caveats: Indirect Causes of Weakness

Hypocalcemia-Related Symptoms

The most relevant concern is hypocalcemia, which can present with symptoms that might be mistaken for muscle weakness 1:

• Muscle cramps, spasms, or tetany
• Paresthesias
• Neuromuscular irritability

High-risk patients for hypocalcemia include:

• Chronic kidney disease (especially eGFR <30 mL/min)
• Vitamin D deficiency
• Malabsorption syndromes
• Patients on dialysis 1

Clinical action: Check calcium, magnesium, and phosphorus within 14 days of injection in at-risk patients. Ensure adequate calcium and vitamin D supplementation before initiating therapy 1.

Atypical Femoral Fractures

While extremely rare, atypical femoral fractures can present with prodromal thigh or groin pain that might be perceived as leg weakness 3, 4. These fractures:

• Occur in the subtrochanteric region or femoral diaphysis
• May present with bilateral symptoms
• Show characteristic radiographic features (transverse fracture line, periosteal callus)
• Risk increases with long-term use (median 7 years) 4

Clinical action: Evaluate any new thigh, hip, or groin pain with imaging, especially in patients on long-term therapy.

Clinical Recommendation

If a patient on Prolia reports leg muscle weakness:

1. Assess for hypocalcemia symptoms (cramps, paresthesias, tetany)

   • Check serum calcium, magnesium, phosphorus, vitamin D
   • Particularly important if patient has CKD or malabsorption

2. Evaluate for atypical femoral fracture if pain is present

   • Obtain bilateral femur radiographs if thigh/groin pain
   • Look for prodromal symptoms

3. Consider alternative causes of muscle weakness

   • Deconditioning from fracture/immobility
   • Concurrent medications (statins, corticosteroids)
   • Underlying neuromuscular conditions
   • Vitamin D deficiency (independent of denosumab)

4. Do not attribute weakness directly to denosumab unless hypocalcemia is documented

The evidence strongly supports that muscle weakness is not a recognized adverse effect of Prolia when used at standard osteoporosis doses (60 mg every 6 months) 1, 5.